BASILEA N | 33.200 / +2.00% |
Date/Time | 05/25 / 17:30 |
Chg. / Chg.(%) | 0.650 / +2.00% |
Bid | 32.850 / 1500 |
Ask | 33.250 / 500 |
Open | 32.500 |
Previous Close | 32.550 |
High | 33.450 |
Low | 32.250 |
Volume [CHF] | 597,016.175 |
Volume [Units] | 18,054 |
Price fixings | 160 |
ISIN | CH0011432447 |
Security | BSLN |
Exchange | SIX Swiss Exchange |
Type | Stock |
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 31.85 | ![]() |
|
SIX Swiss Ex.. | 33.200 | ![]() |
18,054 |
London Domes.. | 33.30 | 1,403 | |
Cboe Europe .. | 32.95 | 757 | |
Turquoise | 33.15 | ![]() |
459 |
Cboe Europe .. | 33.15 | 430 | |
Nasdaq Other.. | 41.0000 | 40 | |
München | 32.300 | 0 | |
Berlin | 32.100 | 0 | |
Frankfurt | 32.2800 | 0 | |
gettex | 32.340 | ||
TradeGate | 30.300 | 33 | |
EUREX | Options |
News
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
03/08/2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
02/15/2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
01/24/2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
01/13/2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
01/11/2022 / 07:15 - GlobeNewswire